ArticleClinical, cosmetic and investigational dermatology2026
Omalizumab in Refractory Adult-Onset Facial Atopic Dermatitis: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Adult-onset facial atopic dermatitis (AFAD) is a distinct subtype of atopic dermatitis that predominantly affects the face and is frequently misdiagnosed as rosacea or other facial dermatoses. The management of AFAD is challenging, particularly in patients who respond poorly to conventional therapies. At present, reports on the use of anti-immunoglobulin E (IgE) therapy in AFAD are limited. Herein, we report a case of AFAD with markedly elevated serum IgE levels that showed a favorable response to omalizumab. Patients and Methods: A retrospective analysis was conducted on the clinical characteristics, laboratory findings, treatment course, and therapeutic outcomes of a patient with AFAD. Pruritus severity was assessed using a visual analog scale (VAS, 0-10). Facial erythema and skin dryness were evaluated using the objective sign components of the SCORAD index. Clinical photographs and objective assessment results were recorded during follow-up. Results: A 41-year-old woman presented with a 10-year history of recurrent facial erythema accompanied by pruritus and burning sensations, with poor responses to multiple conventional systemic and topical treatments. Total serum IgE levels were markedly elevated. The patient received subcutaneous omalizumab at a dose of 300 mg every 4 weeks for a total of three injections. During treatment, facial erythema, scaling, pruritus, and burning sensations gradually improved. Symptom-related scores decreased, and no adverse events were observed in this case. Conclusion: This case suggests that even in the absence of a typical atopic history, omalizumab may represent a potential therapeutic option for patients with adult-onset facial atopic dermatitis who exhibit elevated serum IgE levels and poor responses to conventional treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.